Pharming Group (NASDAQ:PHAR) PT Lowered to $30.00

Pharming Group (NASDAQ:PHAR) had its target price cut by research analysts at Oppenheimer from $31.00 to $30.00 in a research report issued to clients and investors on Monday, Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Oppenheimer’s price objective would indicate a potential upside of 244.83% from the stock’s current price.

Separately, HC Wainwright reiterated a “buy” rating and issued a $37.00 target price on shares of Pharming Group in a research report on Thursday.

Pharming Group Price Performance

PHAR stock opened at $8.70 on Monday. The company’s 50-day moving average price is $8.05 and its two-hundred day moving average price is $8.53. The firm has a market cap of $585.89 million, a P/E ratio of -54.38 and a beta of 0.15. The company has a quick ratio of 2.65, a current ratio of 3.39 and a debt-to-equity ratio of 0.40. Pharming Group has a 12 month low of $6.65 and a 12 month high of $13.20.

Pharming Group (NASDAQ:PHAR) last announced its quarterly earnings data on Thursday, August 1st. The company reported ($0.01) EPS for the quarter. The firm had revenue of $74.09 million for the quarter, compared to analyst estimates of $71.95 million. Pharming Group had a negative net margin of 4.65% and a negative return on equity of 5.69%. During the same quarter in the prior year, the firm earned $0.02 earnings per share. On average, analysts anticipate that Pharming Group will post -0.15 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC increased its position in shares of Pharming Group (NASDAQ:PHAR) by 32.3% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 23,435 shares of the company’s stock after acquiring an additional 5,725 shares during the period. Silverberg Bernstein Capital Management LLC’s holdings in Pharming Group were worth $196,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 0.03% of the company’s stock.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.